An interventional study of Beta-Sitosterol Ointment and Hydrophilic Methacrylate Gel in Episiotomy and Perineal Wound Healing, sponsored by Hamad Medical Corporation. Completed at 1 site in Qatar. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-11.
Sponsored by Hamad Medical Corporation · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This randomized controlled trial compares hydrophilic methacrylate gel versus beta-sitosterol ointment for early episiotomy wound healing. A total of 107 women who underwent mediolateral episiotomy during vaginal delivery were allocated to receive either hydrophilic methacrylate gel (n=53) or beta-sitosterol ointment (n=54). Wound outcomes were assessed by trained observers blinded to treatment allocation and by patients at two time points approximately 12 days apart. The primary outcome was the REEDA score (Redness, Edema, Ecchymosis, Discharge, Approximation). Secondary outcomes included patient-reported pain, cosmetic appearance, satisfaction, perceived treatment effectiveness, ease of application, and likelihood of recommending treatment.
Wound healing following episiotomy is a complex biological process influenced by mechanical stress, inflammatory response, tissue perfusion, and patient-related factors. This prospective randomized single-blinded controlled trial enrolled adult women who underwent mediolateral episiotomy during vaginal delivery at a tertiary care maternity hospital in Qatar. Exclusion criteria included known dermatological conditions affecting wound healing, hypersensitivity to study products, systemic inflammatory disease, chronic conditions delaying healing (e.g., coagulation disorders, diabetes, anemia with Hb \<9 g/dl), prior perineal injury, surgery, or visible lesions, or inability to attend follow-up. A total of 107 women were allocated to receive either hydrophilic methacrylate gel (n=53) or beta-sitosterol ointment (n=54).Outcome assessments were performed by trained observers blinded to treatment allocation and by patients at two time points approximately 12 days apart. Observer-assessed outcomes used the REEDA scale (Redness, Edema, Ecchymosis, Discharge, Approximation). Patient-reported outcomes included pain, cosmetic appearance, overall satisfaction, perceived treatment effectiveness, ease of application, and likelihood of recommending treatment.
Hamad Medical Corporation is the lead sponsor of 139 studies on the registry; 27 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants applied Beta-Sitosterol ointment to the episiotomy/perineal wound site twice daily (morning and evening) for 2 weeks.
Drug: Beta-Sitosterol Ointment
Participants applied Hydrophilic methacrylate gel to the episiotomy/perineal wound site twice daily (morning and evening) for 2 weeks.
Drug: Hydrophilic Methacrylate Gel
Topical ointment containing beta-sitosterol applied to the episiotomy/perineal wound site
Hydrophilic methacrylate-based hydrogel applied to the episiotomy/perineal wound site
Perineal Wound Healing Assessed by REEDA Scale
Measured using the REEDA scale (Redness, Edema, Ecchymosis, Discharge, Approximation) total score, where higher scores indicate worse wound healing, assessed by trained observers blinded to treatment allocation.
Time frame: Assessed at two time points: Day 5 postpartum and Day 12 postpartum
Complete Wound Healing (REEDA = 0) Assessed at Day 12
Proportion of participants with a REEDA total score of 0 (no observed redness, edema, ecchymosis, discharge, or approximation abnormality) at Day 12 postpartum, assessed by trained observers blinded to treatment allocation.
Time frame: Day 12 postpartum
Patient-Reported Pain
Patient-reported pain rated on a 5-category verbal scale (None/Mild/Moderate/Severe/Very severe), categorized as none or mild vs. moderate to very severe.
Time frame: Day 12 postpartum
Patient Satisfaction (Patient-Reported Outcome)
Patient-reported overall satisfaction with treatment (categorized as satisfied/very satisfied vs not satisfied).
Time frame: Day 12 postpartum
Treatment Effectiveness Perception (Patient-Reported Outcome)
Patient-reported perceived effectiveness of treatment (categorized as effective/very effective vs not effective).
Time frame: Day 12 postpartum
Perineal Cosmetic Appearance (Patient-Reported Outcome)
Patient-reported cosmetic appearance of the perineal wound (categorized as improved somewhat/significantly vs no change or worsened).
Time frame: Day 12 postpartum
Ease of Application (Patient-Reported Outcome)
Ease of applying the topical treatment, categorized as easy/very easy vs neutral or difficult.
Time frame: Day 12 postpartum
Likelihood of Treatment Recommendation (Patient-Reported Outcome)
Likelihood of recommending the treatment to others (categorized as likely/definitely recommend vs neutral or unlikely).
Time frame: Day 12 postpartum
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Individual participant data will not be shared. De-identified data may be made available to external collaborators under a separate institutional data use agreement for specific academic purposes, but IPD is not being made available for public sharing.
Ran from Dec 2023 to primary completion in Oct 2024, 9 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.